#Bioretec #Finland #Tampere #RemeOs #Activa

Bioretec Ltd Financial Reports and AGM Schedule for 2026

Bioretec Ltd, a pioneering player in the orthopedic medical device sector, has set an important schedule for its financial reporting and the Annual General Meeting (AGM) for the year 2026. This announcement is crucial for investors and stakeholders, as it outlines the timing of essential financial documents that reflect the company's ongoing performance and future directions.

Key Dates for Financial Reports

In 2025, Bioretec will be releasing several key financial documents:

• - February 13, 2025: The financial statements bulletin covering the period from January to December 2025 will be published.
• - March 13, 2026: The annual report will be released, which includes the Board of Directors' report and financial statements for the fiscal year 2025.
• - May 14, 2026: A business review for the first quarter of 2026 will be provided, outlining the performance and projected growth in this period.
• - August 13, 2026: The half-year report for January to June 2026 will be published, giving insights into the company’s financial trajectory.
• - November 12, 2026: Bioretec will publish a business review for January to September 2026, offering an overview of the operational performance in the third quarter.

These financial reports are particularly critical, as they will be made available online on Bioretec Ltd's investor relations portal (https://bioretec.com/investors/investors-in-english/reports-and-presentations). This allows stakeholders to easily access the data needed to make informed decisions.

Annual General Meeting Details

One of the key moments for shareholders will be the company's Annual General Meeting, which is scheduled for May 8, 2026. At this meeting, shareholders will have the opportunity to discuss the financial reports presented and engage with the Board of Directors on key decisions affecting the future of Bioretec. The specific agenda for the AGM will be communicated separately by the Board of Directors closer to the date, ensuring transparency and thorough communication.

About Bioretec Ltd

Bioretec Ltd is headquartered in Tampere, Finland, and stands at the forefront of orthopedic innovation, particularly with its range of fully biodegradable implant technologies. The company's products are designed to facilitate better healing processes in patients undergoing orthopedic surgeries. Bioretec's proprietary technology focuses on creating implants that integrate seamlessly with human biology, leading to improved surgical outcomes and reduced post-operative complications.

Among its notable product offerings is the RemeOs™ line, developed from a sophisticated magnesium alloy and hybrid composite, which presents strong absorbable materials that enhance recovery outcomes while eliminating the need for removal surgeries. Furthermore, the Activa line includes fully bioabsorbable implants using advanced self-reinforced PLGA, both CE marked and FDA cleared for various applications across different patient groups.

With products sold in over 40 countries globally, Bioretec continues to make significant strides in enhancing orthopedic care through innovation, thus solidifying its position as a leader in the medical device industry.

For further updates and information about Bioretec Ltd's financial performance, innovations, and corporate governance, interested parties can visit official site.

By emphasizing a commitment to transparency and innovation, Bioretec Ltd not only aims to build trust with their investors but also to drive orthopedic care into a new era of efficiency and patient-centric approaches.